{"id":"NCT03766685","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)","officialTitle":"A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-20","primaryCompletion":"2020-07-14","completion":"2020-09-08","firstPosted":"2018-12-06","resultsPosted":"2023-08-08","lastUpdate":"2025-07-14"},"enrollment":172,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis","Moderate to Severe Chronic Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["UCB4940","BKZ"]}],"arms":[{"label":"Bimekizumab-SS","type":"EXPERIMENTAL"},{"label":"Bimekizumab-AI","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection technique using a prefilled safety syringe or an auto-injector.","primaryOutcome":{"measure":"Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL at Week 8, After Training in Self-injection Technique","timeFrame":"Week 8","effectByArm":[{"arm":"Bimekizumab-SS-1mL 320 mg (FAS-s-1mL)","deltaMin":100,"sd":null},{"arm":"Bimekizumab -AI-1mL 320 mg (FAS-a-1mL)","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":39,"countries":["United States","Canada"]},"refs":{"pmids":["40156698","35133113"],"seeAlso":["https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Injection site reaction","Injection site pain"]}}